Skip to main content
Presentation
Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of OPAL Balance, an open label, long-term extension study. Laurentian Conference of Rheumatology, Quebec Canada, May, 2018
Laurentian Conference of Rheumatology (2018)
  • Peter Nash
  • Laura Coates
  • Alan Kivitz
  • Philip Mease, Providence St. Joseph Health
  • Dafna D. Gladman, University of Toronto
  • JA Covarrubias-Cobos
  • Dona Fleishaker
  • Cunshan Wang, Pfizer
  • Sujatha Menon
  • Lara Fallon
  • Thijs Hendrikx
  • Keith Kanik
Disciplines
Publication Date
May, 2018
Location
Quebec
Citation Information
Peter Nash, Laura Coates, Alan Kivitz, Philip Mease, et al.. "Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of OPAL Balance, an open label, long-term extension study. Laurentian Conference of Rheumatology, Quebec Canada, May, 2018" Laurentian Conference of Rheumatology (2018)
Available at: http://works.bepress.com/philip-mease/130/